|
NICE Publishes Appeal Decision On Lapatinib
The National Institute for Health and Clinical Excellence (NICE) has published the outcome of an appeal hearing relating to its draft guidance on the use of lapatinib (Tyverb, GlaxoSmithKline) for certain breast cancer patients...
More... |
| All times are GMT -7. The time now is 01:13 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021